The highly anticipated weight-loss drug Wegovy will be available to patients in Canada starting Monday, offering a new treatment option for those struggling with obesity. Developed by Novo Nordisk, Wegovy is a weekly injection approved for weight loss in patients diagnosed with obesity, as well as those who are significantly overweight and have related medical conditions such as high blood pressure, Type 2 diabetes, or obstructive sleep apnea.
Dr. Sanjeev Sockalingam of Obesity Canada emphasizes the importance of Wegovy as a medical treatment for a serious condition, rather than for cosmetic purposes. The drug contains the same medication as the diabetes drug Ozempic, but at a higher dose, providing clinicians with another tool to help patients manage their weight.
Health Canada approved Wegovy in November 2021 based on studies showing significant weight loss in patients treated with semaglutide compared to those on a placebo. Doctors can prescribe Wegovy to patients with a BMI of 30 or greater, or to those with a BMI of 27 or higher who also have weight-related medical conditions.
The arrival of Wegovy follows a surge in demand for off-label use of Ozempic for weight loss, prompting experts to stress the importance of responsible prescribing. Dr. Ehud Ur, an endocrinologist in Vancouver, emphasizes the need for physicians to carefully assess patients before prescribing Wegovy to ensure it is used appropriately.
As Obesity Canada updates its medication guidelines to include Wegovy, the focus remains on using the drug in conjunction with physical activity and nutrition to address obesity as a medical condition. With Wegovy now available in Canada, patients have a new option to support their weight-loss journey under the guidance of healthcare professionals.